<DOC>
	<DOCNO>NCT00002715</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient advance Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility short term chemotherapy Stanford V regimen ( mechlorethamine , doxorubicin , vinblastine , prednisone , vincristine , bleomycin , etoposide ) follow , indicate , consolidative radiotherapy patient stage IIB , IIIA , IIIB , IV Hodgkin 's lymphoma . - Determine initial response 8 week Stanford V chemotherapy patient . - Assess complete partial response rate 12 week Stanford V chemotherapy patient . - Determine acute toxicity associate treatment . - Determine disease free interval survival follow Stanford V chemotherapy without consolidative radiotherapy patient . OUTLINE : All patient treat Regimen A Stanford V Regimen ; initial bulky , residual , splenic disease achieve CR/PR proceed Regimen B . - Regimen A : Patients receive mechlorethamine IV week 1 , 5 , 9 ; doxorubicin vinblastine IV week 1 , 3 , 5 , 7 , 9 , 11 ; vincristine bleomycin IV week 2 , 4 , 6 , 8 , 10 , 12 ; etoposide IV 30-45 minute 2 consecutive day week 3 , 7 , 11 ; prednisone orally every day day 1-84 . Treatment continue 8-12 week , depend response , absence disease progression unacceptable toxicity . - Regimen B : Patients begin radiotherapy 2-4 week completion Regimen A . Patients receive radiotherapy lung , pleura , extralymphatic site approximately 5 week . Patients follow survival . PROJECTED ACCRUAL : A total 50 patient enter least 16 first 22 patient respond . As 03/96 , expect total 45 patient stage III/IV disease 40 unfavorable stage II disease accrue .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma histology Unfavorable disease require Clinical stage IIIA , IIIB , IV , IIB ( nonbulky ) Locally extensive stage I II either follow : Mediastinal mass great 1/3 maximum intrathoracic diameter Two extranodal sit PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior malignancy except nonmelanomatous skin cancer No significant concurrent illness precludes protocol participation PRIOR CONCURRENT THERAPY : No prior treatment Hodgkin 's lymphoma Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
</DOC>